The journal of nutrition, health & aging

, Volume 15, Issue 1, pp 45–57

Progress in the development of new drugs in Alzheimer’s disease


    • GérontopôleHôpitaux de Toulouse
    • Gérontopôle, Alzheimer’s Disease Research and Clinical Center; Department of Internal Medicine and Clinical GerontologyUniversity Hospital, Purpan-Casselardit
  • F. Nourhashémi
    • GérontopôleHôpitaux de Toulouse
    • Inserm U558
  • C. Hein
    • GérontopôleHôpitaux de Toulouse
  • C. Caillaud
    • GérontopôleHôpitaux de Toulouse
  • B. Vellas
    • GérontopôleHôpitaux de Toulouse
    • Inserm U558

DOI: 10.1007/s12603-011-0012-x

Cite this article as:
Piau, A., Nourhashémi, F., Hein, C. et al. J Nutr Health Aging (2011) 15: 45. doi:10.1007/s12603-011-0012-x


Alzheimer’s disease (AD) is an age-related neurodegenerative disease with a global prevalence estimated at 26.55 million in 2006. During the past decades, several agents have been approved that enhance cognition of AD patients. However, the effectiveness of these treatments are limited or controversial and they do not modify disease progression. Recent advances in understanding AD pathogenesis have led to the development of numerous compounds that might modify the disease process. AD is mainly characterized neuropathologically by the presence of two kinds of protein aggregates: extracellular plaques of Abeta-peptide and intracellular neurofibrillary tangles. Abeta and tau could interfere in an original way contributing to a cascade of events leading to neuronal death and transmitter deficits. Investigation for novel therapeutic approaches targeting the presumed underlying pathogenic mechanisms is major focus of research. Antiamyloid agents targeting production, accumulation, clearance, or toxicity associated with Abeta peptide, are some approaches under investigation to limit extracellular plaques of Abeta-peptide accumulation. We can state as an example: Abeta passive and active immunization, secretases modulation, Abeta degradation enhancement, or antiaggregation and antifibrillization agents. Tau-related therapies are also under clinical investigation but few compounds are available. Another alternative approach under development is neuroprotective agents such as antioxidants, anti-inflammatory drugs, compounds acting against glutamate mediated neurotoxicity. Neurorestorative approaches through neurotrophin or cell therapy also represent a minor avenue in AD research. Finally, statins, receptor for advanced glycation end products inhibitors, thiazolidinediones, insulin, and hormonal therapies are some other ways of research for a therapeutic approach of Alzheimer’s disease. Taking into account AD complexity, it becomes clear that polypharmacology with drugs targeting different sites could be the future treatment approach and a majority of the recent drugs under evaluation seems to act on multiple targets. This article exposes general classes of disease-modifying therapies under investigation.

Key words

Alzheimer’s diseasedisease-modifying therapiesclinical trials

Copyright information

© Serdi and Springer Verlag France 2011